Abstract
Neuropsychiatric and neurodegenerative disorders exhibit cell-type-specific characteristics1–8, yet most transcriptome-wide association studies have been constrained by the use of homogenate brain tissue9–11, limiting their resolution and power. Here, we present a single-nucleus transcriptome-wide association study (snTWAS) leveraging single-nucleus RNA sequencing of over 6 million nuclei from the dorsolateral prefrontal cortex of 1,494 donors across three ancestries—European, African, and Admixed American. We constructed ancestry-specific single-nucleus-derived transcriptomic imputation models (snTIMs) including up to 27 non-overlapping cellular populations, enhancing the resolution of genetically regulated gene expression (GReX) in the brain and uncovering novel gene-trait associations across 12 neuropsychiatric and neurodegenerative traits. Our snTWAS framework revealed cell-type-specific dysregulation of GReX, identifying over 4,000 novel gene-trait associations not detected by bulk tissue approaches. By applying these snTIMs to the Million Veteran Program, we validated major findings and explored the pleiotropy of cell-type-specific GReX, revealing cross-ancestry concordance and fine-mapping causal genes. This approach enhances the discovery of biologically relevant pathways and gene targets, highlighting the importance of cell-type resolution and ancestry-specific models in understanding the genetic architecture of complex brain disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award I01BX004189. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. We thank the participants of the Million Veteran Program, the scientists, clinicians and supportive staff involved in the construction of this biobank, and the scientific computing staff for the expertise that they provided. We thank the computational resources and staff expertise provided by the Scientific Computing at the Icahn School of Medicine at Mount Sinai. This study was also supported by the National Institutes of Health (NIH), Bethesda, MD under award numbers R01AG067025 (PR), R01AG082185 (PR), K08MH122911 (GV), R01AG078657 (GV), BX004189 (PR), R01AG065582 (PR), R01AG067025 (PR), R01MH125246 (PR) and T32MH087004 (KT). Human tissues were obtained from the NIH NeuroBioBank at the Mount Sinai Brain Bank (MSSM; supported by NIMH-75N95019C00049), the Rush Alzheimer's Disease Center (RADC; funding: P30AG10161, P30AG72975, R01AG15819, R01AG17917, R01AG22018, U01AG46152, and U01AG61356), and NIMH-IRP Human Brain Collection Core (HBCC, project # ZIC MH002903). This work was supported in part through the computational and data resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Award (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the VA Central Institutional Review Board (IRB), and participating studies received approval from their respective IRBs. All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
